Dr. Mehrdad Matloubian, MD

Dr. Matloubian practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Matloubian's NPI, 1881658698, was assigned on April 17, 2006. Dr. Matloubian graduated from David Geffen School of Medicine at UCLA in 1996. Dr. Matloubian holds California license G84611.

Dr. Matloubian's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Matloubian's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Matloubian to 3 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Matloubian practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Matloubian's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Matloubian is board certified in rheumatology by the American Board of Internal Medicine. Dr. Matloubian is licensed in California.

Dmand AI lists arteritis, arthritis, fluid in a joint, gout, joint arthropathy, lupus, muscle disease and muscle pain, fibromyalgia, and limb pain among the conditions Dr. Matloubian treats.

CMS data shows 465 Medicare services from Dr. Matloubian across 5 procedure codes in 2024, for 157 Medicare patients. Medicare paid $31,375 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 157 Medicare patients who saw Dr. Matloubian in 2024. The largest group is 75 to 84, with 62 patients. 75% of them have arthritis, and 74% have high blood pressure. 29% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Matloubian's median patient age at 62, with 66% women.

In 2024, Dr. Matloubian wrote 658 Medicare Part D claims for 103 patients. 76% of them were for generic drugs. CMS names the drug for 547 of them, across 13 drugs with 11 or more claims each, at $504,074 in total drug cost. In 2023, CMS named 546 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Matloubian for performance year 2024, reported as part of a group. Dr. Matloubian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Matloubian as offering telehealth.

Dmand AI links 45 papers to Dr. Matloubian, published from 2004 to 2024. 2022 was the busiest year, with 4. The most frequent topics are Lymphocytic choriomeningitis virus, Mice, Inbred C57BL and CD8-Positive T-Lymphocytes. Dr. Matloubian has published most often in J Virol. Dr. Matloubian's most frequent co-authors are Rafi Syed Ahmed, MD, Lianne Simone Gensler, MD and Mary Chiyoko Nakamura, MD.

CMS Open Payments shows 15 general payments to Dr. Matloubian from 4 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 80% of the total. GlaxoSmithKline, LLC. paid the most, $138.

Dmand AI lists 3 awards for Dr. Matloubian, most recently CMS Stage 1 EHR in 2013.

Dr. Matloubian graduated from David Geffen School of Medicine at UCLA in 1996.

Dr. Matloubian is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.